摘要
目的研究参麦注射液联合左西孟旦对脓毒症患者治疗效果。方法选取本院2016年4月-2018年4月收治的脓毒症患者142例为研究对象,按照随机数表法分为联用组和对照组,每组71例。对照组在常规干预的基础上给予左西孟旦静脉注射治疗,联用组在对照组的基础上给予参麦注射液联合处理。治疗前后分别对两组患者血清白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、白细胞介素-10(IL-10)、肿瘤坏死因子-α(TNF-α)、血管紧张素转化酶(ACE)水平、左室短轴缩短率(FS)、左室射血分数(LVEF)及急性生理与慢性健康评分(APACHEⅡ)、全身性感染相关器官衰竭评分(SOFA)进行收集,评估疾病进程及心肺等功能。结果联用组患者治疗后血清IL-6、IL-8、IL-10、TNF-α水平分别为(30.65±5.92)pg/mL、(14.73±2.85)pg/mL、(13.98±2.06)pg/mL、(12.47±2.18)pg/mL,显著低于对照组的(52.38±10.43)pg/mL、(26.34±5.51)pg/mL、(15.45±2.22)pg/mL、(19.00±3.73)pg/mL,差异有统计学意义(P<0.05);联用组患者治疗后FS、LVEF水平分别为(40.68±7.95)%、(55.27±11.36)%,显著高于对照组的(29.26±5.82)%、(43.20±8.14)%,差异有统计学意义(P<0.05);联用组治疗后ACE水平为(37.67±6.93)U/L,显著低于对照组(46.32±8.81)U/L,差异有统计学意义(P<0.05);联用组患者治疗后APACHEⅡ评分及SOFA评分分别为(13.71±2.42)分、(0.87±0.16)分,显著低于对照组的(18.35±3.61)分、(3.59±0.75)分,差异有统计学意义(P<0.05)。结论参麦注射液联合左西孟旦可有效控制脓毒症患者疾病进程,改善心肺功能,缓解器官功能障碍,提高治疗效果。
Objective To study the therapeutic effect of Shenmai injection combined with levosimendan on sepsis patients.Methods 142 patients with sepsis admitted to our hospital from April 2016 to April 2018 were selected as the study subjects;they were divided into combined group and control group according to random number table method,with 71 cases in each group.The control group was treated with Levosimendan intravenous injection on the basis of routine intervention,and the combined group was treated with Shenmai Injection on the basis of the control group.Serum interleukin-6(IL-6),interleukin-8(IL-8),interleukin-10(IL-10),tumor necrosis factor-α(TNF-α),angiotensin converting enzyme(ACE)level,fractional shortening(FS),leftventricularejectionfraction(LVEF),AcutePhysiologyAndChronicHealthScore(APACHEⅡ),SepsisRelated Organ Failure Assessment score(SOFA)were collected before and after treatment,assessment of disease progression and cardiopulmonary function.Results Serum levels of IL-6,IL-8,IL-10,TNF-αin the combined group after treatment were(30.65±5.92)pg/mL,(14.73±2.85)pg/mL,(13.98±2.06)pg/mL and(12.47±2.18)pg/mL,respectively,significantly lower than those in the control group[(52.38±10.43)pg/mL,(26.34±5.51)pg/mL,(15.45±2.22)pg/mL and(19.00±3.73)pg/mL],respectively(P<0.05).The levels of FS and LVEF in the combined group after treatment were(40.68±7.95)%and(55.27±11.36)%,respectively,significantly higher than those in the control group(29.26±5.82)%and(43.20±8.14)%,respectively(P<0.05).ACE level in the combined group after treatment was(37.67±6.93)U/L,which was significantly lower than that in the control group(46.32±8.81)U/L(P<0.05).APACHEⅡscore and SOFA score in the combined group after treatment were(13.71±2.42)and(0.87±0.16),respectively,which were significantly lower than those in the control group(18.35±3.61)and(3.59±0.75),respectively(P<0.05).Conclusion Shenmai Injection combined with Levosimendan could effectively control the course of sepsis,improve cardiopulmonary function,alleviate organ dysfunction,and improve therapeutic effect.
作者
刘文悦
卢清龙
魏晓华
提长斌
马增香
LIU Wen-yue;LU Qing-long;WEI Xiao-hua;TI Chang-bin;MA Zeng-xiang(Department of Critical Care Medicine,Cangzhou People's Hospital,Cangzhou,Hebei 061000,China)
出处
《热带医学杂志》
CAS
2019年第5期645-648,共4页
Journal of Tropical Medicine
基金
沧州市重点研发计划指导项目(172302098)
